TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01685632

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery with IPCH
Description: surgical debulking and extensive tumoral resection after laparotomy under general anesthesia~* 7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery and 3 samples during the 3 following days (at 24th, 48th and 72th hours).~* 6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum , each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Without surgery and without IPCH
Description: The patients is opened and recused during the surgery because of extended carcinosis and closed without resection neither IPCH.~* 7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery (2 hours before IPCH, 1.5hours after IPCH, 4 hours after IPCH) and 3 samples during the 3 following days (at 24th, 48th and 72th hours).~* 6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum, each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH
Study: NCT02875912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Care Rituals
Description: Family members being enrolled are given a pamphlet outlining the Family Care Rituals. They are informed of the opportunity to perform these rituals, but that they are in no way obligated to do so.~Family members are then surveyed at enrollment, and 90 days post ICU discharge for symptoms of PTSD, as well as depression, and anxiety.~Family members, day-time nursing, and attending physicians are surveyed for concordance of care at enrollment and ICU day 5.~Demographic information is also collected on the patient and the family members at enrollment Nursing completes surveys while the patient is in the ICU noting what care rituals, if any, are being performed. Additionally, they are asked to complete a survey indicating their opinion of the impact on the care they deliver
Study: NCT02422303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: Ketamine 0.5mg/kg will be given intravenously to group A at induction of general anesthesia.
Study: NCT01072383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT061
Description: administration of BT061 either intravenous or subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo treatment
Description: administration of the end formulation buffer of BT061 without active ingredient, either subcutaneous or intravenous
Study: NCT03534414

Intervention type: DIETARY_SUPPLEMENT
Intervention: Portfolio Dietary Pattern
Description: Portfolio Dietary Pattern consisting of 4 food components, including:~1. plant sterols (sterol-enriched margarine or supplement)~2. viscous soluble fibres (oats, barley, psyllium, eggplant, okra, etc)~3. plant protein (soy products and pulses), and~4. nuts (tree nuts and peanuts)

Intervention type: DIETARY_SUPPLEMENT
Intervention: NCEP Based Diet
Description: A low saturated fat, low cholesterol diet.

Intervention type: DIETARY_SUPPLEMENT
Intervention: NCEP Based Diet
Description: A low saturated fat, low cholesterol diet.
Study: NCT02433561

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraplexic catheter location (Contiplex® C, B. Braun Melsungen, AG)
Description: The catheter tip will be placed with the aid of the ultrasound within the brachial plexus between C5 and C6

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraplexic catheter location (Contiplex® C, B. Braun Melsungen, AG)
Description: The catheter tip will be placed with the aid of the ultrasound 2 mm away from the lateral part of the brachial plexus
Study: NCT02321410

Intervention type: OTHER
Group type: OTHER
Intervention: Contrast enhanced ultrasound of the carotid plaque
Description: visual grading of neovessel

Intervention type: OTHER
Group type: OTHER
Intervention: Dynamic contrast-enhanced carotid plaque MRI
Description: quantitative analysis of gadolinium enchantment in a region of interest
Study: NCT00313300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Tablets, Oral, 2.5 mg, twice daily, 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Tablets, Oral, 10 mg, once daily, 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0, twice daily, 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Tablets, Oral 10 mg, twice daily, 26 weeks
Study: NCT01334346

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nike Pegasus
Description: Conventional neutral supportive running footwear. Non minimalist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nike Free 3.0
Description: Partial minimalist shoe with partially elevated heel, but with increased mid-sole flexibility.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibram Five Fingers Shoe
Description: Full minimalist shoe. Virtually no mid-sole, therefore no heel elevation or forefoot rockering. A proxy for a barefoot running condition.
Study: NCT00428792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate 20 mg long-acting capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate 20 mg long-acting capsules
Study: NCT01485575

Intervention type: PROCEDURE
Intervention: Use of intraoperative filters in vitrectomy
Description: During vitrectomy with xenon endoillumination, an orange, green and a yellow filter are applied sequentially to determine which one produces the best contrast behavior of vital dyes
Study: NCT01686022

Intervention type: OTHER
Intervention: Immunoblot
Description: serum specific IgE binds to grass extract by immunoblot
Study: NCT01290484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil oral tablet three times daily
Study: NCT03883022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: with U-VANCO (vancomycin hydrochloride)
Description: 1 gm or 2 gm mixed with autogenous cancellous bone graft

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: without U-VANCO (vancomycin hydrochloride)
Description: no vancomycin added
Study: NCT03266484

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Mixture
Description: The probiotic supplement contains 8 different strains of bacteria and participants will be dosed in two dosages per a total of 40 billion bacteria daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo which is identical to the probiotic mixture. Participants will be dosed in two dosages daily.
Study: NCT00708604

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Islet Transplantation
Description: Islet Transplantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Islet cell transplantation
Description: Islet cell transplantation will occur through the portal vein.
Study: NCT00742443

Intervention type: DRUG
Group type: OTHER
Intervention: Juvista (avotermin)
Description: 100ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure

Intervention type: DRUG
Group type: OTHER
Intervention: Juvista (avotermin)
Description: 250ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure

Intervention type: DRUG
Group type: OTHER
Intervention: Juvista (avotermin)
Description: 250ng/100µL Juvista administered to each linear centimetre of the margins of both wound segments by intradermal injection immediately after and then 24h after wound closure
Study: NCT01742624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: oral
Study: NCT02564159

Intervention type: OTHER
Group type: OTHER
Intervention: Measure of quadriceps thickness with ultrasonography and albumin/prealbumin levels
Description: * Evaluation of quadriceps diameter on the anterior aspect of the thigh using the mid-distance between the anterior superior iliac spine and the upper pole of the patella ;~* Biospecimen collection: Blood samples (prealbumin levels, C-reactive protein, Interleukin-1, Interleukin-6, TNF-alpha and PATROL test™)collection of albumin and prealbumin levels

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measure of quadriceps thickness with ultrasonography and albumin/prealbumin levels
Description: * Evaluation of quadriceps diameter on the anterior aspect of the thigh using the mid-distance between the anterior superior iliac spine and the upper pole of the patella ;~* Biospecimen collection: Blood samples (prealbumin levels, C-reactive protein, Interleukin-1, Interleukin-6, TNF-alpha and PATROL test™)collection of albumin and prealbumin levels
Study: NCT03144141

Intervention type: OTHER
Group type: OTHER
Intervention: Electrical recording of uterine activity by EHG either directly at the emergency or at the hospitalization
Description: Electrical recording of uterine activity by EHG either directly at the emergency or at the hospitalization
Study: NCT04211610

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine sampling
Description: * Blood tests - hs-cTnT, hs-cTnI, complete metabolic panel including urea, creatinine, albumin and myoglobin~* Urine tests - hs-cTnT, hs-cTnI, urea, creatinine, albumin, total protein, β2-microglobulin.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine sampling
Description: * Blood tests - hs-cTnT, hs-cTnI, complete metabolic panel including urea, creatinine, albumin and myoglobin~* Urine tests - hs-cTnT, hs-cTnI, urea, creatinine, albumin, total protein, β2-microglobulin.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine sampling
Description: * Blood tests - hs-cTnT, hs-cTnI, complete metabolic panel including urea, creatinine, albumin and myoglobin~* Urine tests - hs-cTnT, hs-cTnI, urea, creatinine, albumin, total protein, β2-microglobulin.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine sampling
Description: * Blood tests - hs-cTnT, hs-cTnI, complete metabolic panel including urea, creatinine, albumin and myoglobin~* Urine tests - hs-cTnT, hs-cTnI, urea, creatinine, albumin, total protein, β2-microglobulin.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine sampling
Description: * Blood tests - hs-cTnT, hs-cTnI, complete metabolic panel including urea, creatinine, albumin and myoglobin~* Urine tests - hs-cTnT, hs-cTnI, urea, creatinine, albumin, total protein, β2-microglobulin.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine sampling
Description: * Blood tests - hs-cTnT, hs-cTnI, complete metabolic panel including urea, creatinine, albumin and myoglobin~* Urine tests - hs-cTnT, hs-cTnI, urea, creatinine, albumin, total protein, β2-microglobulin.
Study: NCT03342469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Food Coloring
Description: 225mg mixed powdered Artificial Food Coloring (AFC)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Food Coloring
Description: 225mg mixed powdered Artificial Food Coloring (AFC)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Food Coloring
Description: 225mg mixed powdered Artificial Food Coloring (AFC)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Food Coloring
Description: 225mg mixed powdered Artificial Food Coloring (AFC)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo chocolate cookies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo chocolate cookies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo chocolate cookies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo chocolate cookies
Study: NCT00943319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Daily intravenous dosing to target AVC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine dosing will be based on actual body weight. Fludarabine will be infused over 30 minutes before busulfan treatment dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: All patients will receive premedication for Campath (daily doses of 20 mg are repeated for up to five times).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Infusion of bone marrow and donors(related/ unrelated).
Study: NCT03097328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-228
Description: TAK-228 works to inhibit or interfere with cellular functions involved in cell growth and survival. TAK-228 specifically targets a type of protein that can make chemicals that trigger cell growth, including cancer cell growth
Study: NCT02734589

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal transplantation
Description: Transplantation of fecal bacteria from a healthy individual into a recipient- ulcerative colitis patient via colonoscopy and enemas

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unique novel Diet for UC and Unique novel Diet for the donor + FMT
Description: A developed unique diet that is geared to induces remission and decreases inflammation in patients with active UC. Also a conditioning diet for healthy subjects to be used by the donor prior to transplantation- a developed unique diet for two weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unique novel Diet for UC
Description: A developed diet that is geared to induces remission and decreases inflammation in patients with active UC.
Study: NCT03272854

Intervention type: OTHER
Intervention: No intervention performed, the study is observational
Study: NCT04148937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3475070
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3475070
Description: Administered orally
Study: NCT00883558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regular human insulin
Study: NCT04148937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3475070
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3475070
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3475070
Description: Administered orally
Study: NCT00883558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human hyaluronidase PH20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Study: NCT01635751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, fasted)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after high fat meal)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, fasted)
Study: NCT01620385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ciPDA
Description: The ciPDA Research Platform device was designed as a research tool for cochlear implant research.
Study: NCT03925597

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber cycles
Description: Participants will take 20g per day of each fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks before starting the next fiber supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber cycles
Description: Participants will take 20g per day of each fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks before starting the next fiber supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber cycles
Description: Participants will take 20g per day of each fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks before starting the next fiber supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber cycles
Description: Participants will take 20g per day of each fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks before starting the next fiber supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber cycles
Description: Participants will take 20g per day of each fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks before starting the next fiber supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber cycles
Description: Participants will take 20g per day of each fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks before starting the next fiber supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber cycles
Description: Participants will take 20g per day of each fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks before starting the next fiber supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber cycles
Description: Participants will take 20g per day of each fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks before starting the next fiber supplement.
Study: NCT00682916

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Y288
Description: Subjects will take 2 tablets per fat containing meal, 3 times a day, within one hour of consuming the meal
Study: NCT03925597

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber cycles
Description: Participants will take 20g per day of each fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks before starting the next fiber supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber cycles
Description: Participants will take 20g per day of each fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks before starting the next fiber supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber cycles
Description: Participants will take 20g per day of each fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks before starting the next fiber supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber cycles
Description: Participants will take 20g per day of each fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks before starting the next fiber supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber cycles
Description: Participants will take 20g per day of each fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks before starting the next fiber supplement.
Study: NCT04148937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered IV
Study: NCT03925597

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber cycles
Description: Participants will take 20g per day of each fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks before starting the next fiber supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber cycles
Description: Participants will take 20g per day of each fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks before starting the next fiber supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber cycles
Description: Participants will take 20g per day of each fiber supplement for 3 weeks, followed by a washout period of at least 6-8 weeks before starting the next fiber supplement.
Study: NCT02785744

Intervention type: OTHER
Intervention: Gaucher disease DNA mutation analysis
Study: NCT04637750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: The GPs randomized to the intervention arm will receive a feedback informing on their absolute number of patients treated with at least one PPI during the baseline period and if they have been prescribed above or below the median of appropriate prescriptions rate in their local area. They will be also provided with a scientific document including technical details on AIFA reimbursement criteria (NOTA 1 and 48), short hints about adverse events related to PPI long- term use in older patients and recommendation on how to discontinue PPI therapy (i.e. gradual step down administration to avoid paradoxical effect).
Study: NCT01568996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: broccoli sprout extract - sulforaphane (BSE-SFN)
Description: 50 µmol capsules, taken orally, once a day for 28 days